Abstract
Approved first-line (1L) treatments for BRAF-mutant (BRAF-MT) advanced melanoma include nivolumab plus ipilimumab (NIVO + IPI), anti–PD-1 monotherapy, and BRAF plus MEK inhibitors (BRAFi + MEKi). Clinical trial data comparing these options are limited. A real-world study in patients (pts) with BRAF-MT melanoma showed 3-year overall survival (OS) of 58% and 27% with NIVO + IPI and BRAFi + MEKi, respectively (Pavlick AC, et al. EADO 2020). The longer-term follow-up is presented here.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
